Department of War Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program

Amendment / Modification

• The "Due Date" for RFQ HT9402-26-Q-9302 has been updated.

• Original Offer Due Date: June 29, 2026, 12:00 PM CDT

• Updated Offer Due Date: May 28, 2026, 12:00 PM CDT

• Offer Due Date

• The deadline for submitting offers has been moved to an earlier date.

Solicitation / RFP / RFQ

This Request for Quotation (RFQ) seeks pricing for pharmaceutical agents to be considered for placement on the Department of War (DOW) Uniform Formulary (UF). The goal is to establish an effective and efficient pharmacy benefits program for the Military Health System (MHS). Offers may lead to the award of Uniform Formulary Blanket Purchase Agreements (UF BPA) and Uniform Formulary Additional Discount Program (UF ADP) Agreements.

• Manufacturers must submit quotes for pharmaceutical agents identified for placement on the UF.

• Quotes will be considered for inclusion on the UF, Basic Core Formulary (BCF), and Extended Core Formulary (ECF).

• Pricing must be submitted for both Military Treatment Facilities (MTFs)/TRICARE Mail Order Pharmacy (TMOP) via UF BPA, and for refunds via UF ADP for TRICARE retail network pharmacies.

• Specific requirements for UF BPA include providing prices for all NDC-11s for a given agent, potentially excluding institutional/hospital unit dose NDCs with approval. Prices must be equal to or lower than FSS/National Contract prices.

• Specific requirements for UF ADP include providing refund quotes as a percentage of the most recent annual Non-Federal Average Manufacturer Price (Non-FAMP).

• Companies must be registered in the System for Award Management (SAM).

• UF BPA price quotes are valid for 180 days.

• UF ADP refund quotes are valid for 180 days.

• The period of performance for the resulting pricing agreement is contingent upon formulary status changes or reevaluation of the drug class.

• Pre-Quotation Teleconference: May 13, 2026, 1:00 PM CST.

• Responses to Clinical Questions Due: May 28, 2026.

• Quotes Due: May 28, 2026, 12:00 PM CST.

• P&T Committee Meeting: August 5-6, 2026.

• Quotes must be submitted electronically to the RFQ Point of Contact.

• Evaluation will consider clinical effectiveness and cost-effectiveness.

• For UF BPA, evaluation price will be the UF BPA price quote or, if none, the lower of the Big 4 or FSS price.

• For UF ADP, evaluation will consider the refund quote as part of cost-effectiveness.

• No specific set-asides are mentioned.

• Companies must have an existing FSS contract/Interim Agreement for quoted agents.

• The document includes detailed appendices for Manufacturer Quote Submission Checklist (Appendix 1), UF BPA (Appendix 2), UF ADP (Appendix 3), and NDC Price List (Appendix 4).

• The DOW reserves the right to reject or decline specific formulations or NDC-11s.

Forms / Attachments / Pricing Sheets

This document provides Frequently Asked Questions (FAQ) regarding the Price Appendix, which is likely a spreadsheet used for submitting pricing information for a solicitation.

• BPA (Blanket Purchase Agreement) Pricing: Instructions on how to fill out the spreadsheet for BPAs, including which cells are editable (yellow), auto-population features based on Package Size and Price per NDC, and how to indicate non-submission of a quote.
• ADP (non-FAMP Discount) Pricing: Guidance for entering non-FAMP prices and Current Annual Federal Ceiling Prices, with auto-calculation for Total Calculated Refund. It also explains how a 0.0000% Additional offered refund is indicated.
• ADP (WAC Discount) Pricing: Instructions for products without a FCP (e.g., diabetic supplies). It details how to input WAC prices and indicates how a 0.0000% WAC Discount is highlighted.
• NDC Tables: For all sections, bidders are provided tables for 10 different National Drug Codes (NDCs) and only need to fill out tables relevant to their NDCs. Instructions are provided for requesting additional tables if more than 10 NDCs are needed.
• Contact Information: Bidders are directed to contact Points of Contact (POCs) on the RFQ document for questions or concerns about filling out the tables, or if they need more than 10 NDC tables.

This FAQ is crucial for bidders to correctly understand and complete the pricing appendix/spreadsheet. It clarifies how to input pricing data, what fields are auto-calculated, how to indicate non-participation for specific items, and how to obtain additional tables if necessary. Failure to follow these instructions could lead to incomplete or incorrect pricing submissions.

Solicitation / RFP / RFQ

This Request for Quotation (RFQ) seeks pricing for pharmaceutical agents to be considered for placement on the Department of War (DOW) Uniform Formulary (UF). The DOW is establishing an integrated pharmacy benefits program for the Military Health System (MHS) to ensure cost-effective and clinically effective pharmaceutical options. This RFQ aims to identify agents for the UF, and potentially award UF Blanket Purchase Agreements (UF BPA) and UF Additional Discount Program (UF ADP) Agreements.

• Manufacturers must submit quotes for pharmaceutical agents, including pricing for Military Treatment Facilities (MTFs) and TRICARE Mail Order Pharmacy (TMOP) via UF BPA.

• Manufacturers must also submit refund quotes for agents dispensed through the TRICARE retail network via UF ADP.

• Quotes must include all relevant National Drug Codes (NDCs) for the pharmaceutical agent.

• Pricing must be submitted on a NDC Price List.

• Companies must be registered in the System for Award Management (SAM).

• Quotes must be TAA compliant.

• The RFQ anticipates the award of UF Blanket Purchase Agreements (UF BPA) and UF Additional Discount Program (UF ADP) Agreements.

• UF BPA price quotes are to be valid for 180 days.

• UF ADP refund quotes are contingent upon the agent being placed on the UF, at least in the formulary (2nd) cost share tier.

• Pre-Quotation Teleconference: May 13, 2026, 1:00 PM CST.

• Responses to Clinical Questions Due: June 29, 2026.

• Quotes Due: June 29, 2026, 12:00 PM CST.

• P&T Committee Meeting: August 5-6, 2026.

• Evaluation will consider clinical effectiveness and cost-effectiveness.

• Quotes must be submitted electronically to the RFQ Point of Contact.

• No specific set-aside is mentioned. However, the process involves the DOW P&T Committee's evaluation and recommendations.

• The document includes detailed instructions for submitting UF BPA and UF ADP quotes, including specific appendices for each.

• Definitions for terms like Basic Core Formulary (BCF), Extended Core Formulary (ECF), and Uniform Formulary (UF) are provided.

• The document outlines the evaluation criteria, emphasizing relative clinical and cost-effectiveness.

Form / Attachment / Pricing Sheet

This document contains pricing information and formulary details for antihypertensive agents, specifically for the August 2026 P&T Committee Meeting. It includes Blanket Purchase Agreement (BPA) appendices and Additional Discount Program (ADP) appendices, detailing pricing scenarios based on Uniform Formulary (UF) classes and subclasses.

• BPA Appendix: Lists NDC Number, Drug Name, Strength, Dosage Form, Package Size, and pricing per NDC and per Unit for various formulary scenarios (Uniform Formulary and Non-Formulary). It specifies that prices are for Military Treatment Facility & Mail Order and indicates "NO QUOTE" for certain scenarios, with a note to confirm intent not to submit a quote if cells highlight red.
• ADP (non-FAMP Discount) Appendix: Details TRICARE Retail Refund information, including Non-FAMP Price of Drug Per FCP Package, Additional Offered Refund Per FCP Package, Current Annual Federal Ceiling Price Per FCP Package, Standard Refund Per FCP, and Total Calculated Retail Refund Per FCP Package. It also outlines formulary scenarios (Tier 2 and Tier 3) and notes that the quoted additional refund percentage remains static, but the annual non-FAMP may change.
• ADP (WAC Discount) Appendix: Provides pricing based on Wholesale Acquisition Cost (WAC), including WAC Price of Drug, WAC Discount, and Total Calculated Retail Refund per Package. WAC is used for products without an FCP. The WAC discount percentage is static.
• Class Notes: Applicable to all sections, these notes mention that agents will be reviewed at the P&T Committee meeting, Prior Authorization (PA) may apply, and agents may be considered for special reimbursement methods or exclusion from the TRICARE pharmacy benefit program. Agents not submitted or selected for RFQ may be designated non-step preferred.
• Quotes Due: May 28, 2026.

This document is crucial for bidders offering antihypertensive agents. It outlines the specific pricing structures (BPA, non-FAMP, WAC), refund calculations, and formulary tiers relevant to the opportunity. Bidders must understand these pricing requirements and submission instructions to prepare accurate quotes. The "Quotes due" date is a critical deadline.

Form / Attachment / Pricing Sheet

This document contains pricing information and formulary details for Oncological Agents, specifically Glucocorticoid Receptor Antagonists, relevant to the August 2026 P&T Committee Meeting. It includes two main sheets: 'BPA' (Blanket Purchase Agreement) and 'ADP' (Additional Discount Program) with sub-sections for non-FAMP and WAC discounts.

• BPA Sheet: Lists Uniform Formulary Class (ONCOLOGICAL AGENTS) and Subclass (GLUCOCORTICOID RECEPTOR ANTAGONIST). It outlines P&T Committee Meeting dates (August 5-6, 2026) and quote due dates (May 28, 2026). It details formulary scenarios (Uniform Formulary, Non-Formulary) and indicates 'NO QUOTE' for specific NDC numbers, drug names, strengths, dosage forms, and package sizes. Manufacturers are instructed to submit a Quote Review Checklist and executed signature pages.
• ADP (non-FAMP Discount) Sheet: Details the Additional Discount Program for non-FAMP (Federal Ceiling Price) discounts. It includes calculations for Total Calculated Refund Per FCP and specifies pricing based on Non-FAMP Price of Drug Per FCP Package and Additional Offered Refund Per FCP Package. It also references Current Annual Federal Ceiling Price and Standard Refund Per FCP.
• ADP (WAC Discount) Sheet: Details the Additional Discount Program using Wholesale Acquisition Cost (WAC). It outlines WAC Price of Drug and WAC Discount percentages. WAC is used for products without an FCP or for covered drugs.
• Class Notes: Applicable to all sheets, these notes mention that agents will be reviewed by the P&T Committee, Prior Authorization (PA) may apply, and agents may be considered for special reimbursement methods or exclusion from the TRICARE pharmacy benefit program. Agents with unsubmitted or unselected RFQs may be designated non-step preferred.

This document is crucial for manufacturers of Glucocorticoid Receptor Antagonist oncological agents. It provides specific deadlines for quotes (May 28, 2026) and outlines the pricing structures (BPA, non-FAMP discount, WAC discount) and formulary scenarios under which their products will be evaluated. Bidders must carefully review the pricing requirements and submission instructions to ensure compliance and competitive quoting for inclusion in the Uniform Formulary.

Forms / Attachments / Pricing Sheets

This document contains pricing information and discount program appendices related to the Uniform Formulary (UF) for Immunosuppressives, specifically for the August 2026 P&T Committee Meeting. It includes details for Blanket Purchase Agreements (BPAs) and Additional Discount Programs (ADP) based on non-FAMP (Federal Ceiling Price) and WAC (Wholesale Acquisition Cost) discounts.

• BPA Sheet: Lists NDC numbers, drug names, strengths, dosage forms, and package sizes for Immunosuppressives. It outlines "Formulary Scenarios" (Uniform Formulary and Non-Formulary) and indicates "NO QUOTE" for specific scenarios, suggesting these may not be open for bidding or require specific conditions. It also notes that if a cell highlights red, intent not to submit a quote should be confirmed.
• ADP (non-FAMP Discount) Sheet: Details pricing and refund calculations based on non-FAMP prices and an additional offered refund percentage. It specifies "Tier 2" and "Tier 3" formulary categories and includes fields for Non-FAMP Price, Additional Offered Refund, Current Annual Federal Ceiling Price, Standard Refund, and Total Calculated Retail Refund.
• ADP (WAC Discount) Sheet: Outlines pricing and refund calculations based on Wholesale Acquisition Cost (WAC). It specifies "Tier 2" and "Tier 3" formulary categories and includes fields for WAC Price, WAC Discount, and Total Calculated Retail Refund.
• General Notes: Applicable to all sheets include reminders to submit the Quote Review Checklist and executed signature pages. Class notes mention that agents will be reviewed by the P&T Committee, Prior Authorization may apply, and agents could be considered for special reimbursement methods or exclusion from the TRICARE pharmacy benefit program. Step Therapy Addendum notes that agents with RFQs not submitted or selected may be designated non-step preferred.

This document is crucial for potential bidders in the pharmaceutical sector, particularly those dealing with immunosuppressive drugs. It provides specific pricing structures, discount program requirements (non-FAMP and WAC), and deadlines for quotes (May 28, 2026). Bidders must understand these pricing models and discount expectations to prepare competitive quotes. The "NO QUOTE" indicators and red cell highlighting instructions are critical for determining which products or scenarios are open for bidding and how to respond.

Form / Attachment / Pricing Sheet

This document contains pricing information and formulary details for Vitamins, specifically Water Soluble, related to the August 2026 P&T Committee Meeting. It includes appendices for Blanket Purchase Agreements (BPA), Additional Discount Programs (ADP) with non-FAMP discounts, and ADP with WAC discounts.

• BPA Appendix: Lists NDC numbers, drug names, strengths, dosage forms, package sizes, and pricing scenarios (Uniform Formulary, Non-Formulary). It indicates "NO QUOTE" for listed scenarios and prompts confirmation if a quote will not be submitted.
• ADP (non-FAMP Discount) Appendix: Details TRICARE Retail Refund calculations based on Non-FAMP Price of Drug Per FCP Package, Additional Offered Refund Per FCP Package, Current Annual Federal Ceiling Price Per FCP Package, and Standard Refund Per FCP. It also includes formulary scenarios (Tier 2, Tier 3) and prompts confirmation if a quote will not be submitted.
• ADP (WAC Discount) Appendix: Outlines TRICARE Retail Refund calculations based on WAC Price of Drug and WAC Discount. It includes formulary scenarios (Tier 2, Tier 3) and prompts confirmation if a quote will not be submitted.
• General Notes: Applicable to all sections, these notes remind manufacturers to submit the Quote Review Checklist and executed signature pages. They also clarify pricing per unit of measure and the calculation of refunds.

This document is crucial for bidders interested in supplying Water Soluble Vitamins. It outlines the specific pricing structures (BPA, non-FAMP, WAC discounts), refund calculations, and submission requirements. The "Quotes due" date is May 28, 2026. Bidders must pay close attention to the "Formulary Scenarios" and the instructions regarding the submission of quotes or confirmation of non-submission, especially where cells are highlighted red.

Other / Unclassified

This document outlines the process for the formulary placement of newly FDA-approved innovator drugs within the TRICARE Pharmacy Benefits Program. It references a Final Rule published in the Federal Register on July 27, 2015, which clarifies the process and provides up to 120 days for the Pharmacy and Therapeutics (P&T) Committee to recommend tier placement.

• Drug Evaluation: Innovator drugs evaluated by the P&T Committee are FDA-approved medications under specific application types (BLA, NDA). The committee may also select other NDA chemical type innovator drugs.
• Pending Status: Drugs approved by the FDA on or after August 26, 2015, will be assigned a pending status and treated as non-formulary drugs until evaluated.
• Review Schedule: Drugs approved close to a P&T Committee meeting will be considered at the subsequent quarterly meeting. Tier status review may be deferred if pricing information is not available 30 days prior to the meeting.
• Cost-Effectiveness: The committee will review the relative cost-effectiveness of agents using available pricing.
• Solicitation: The government will solicit Uniform Formulary Blanket Purchase Agreement (UF BPA) and Additional Discount Program (UF ADP) quotes for newly approved drugs. Manufacturers will have three solicitation windows to submit price concessions.
• Tier Designation: Drugs will be considered for Tier 1, Tier 2, Tier 3, and Tier 4/Not Covered based on clinical and cost-effectiveness information.
• Information Posting: Drugs to be reviewed will be posted on the health.mil/pandt page approximately 30 days before the meeting.
• Distribution and Pricing Agreement (DAPA): Pharmaceutical manufacturers are not obligated to obtain a DAPA, but information on establishing one can be obtained from the Defense Logistics Agency (DLA).
• Availability: Innovator drugs are generally designated as Tier 3 and available at MTFs only if medical necessity criteria are met. Otherwise, they are available through TMOP and retail pharmacies at a Tier 3 copay, or a Tier 2 copay if medical necessity criteria are met.
• Presentations: DoD will not entertain innovator drug clinical presentations due to the volume of newly approved drugs.